Trastuzumab Deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

DAISY is a multicenter French clinical trial - NCT04132960 - aiming at assessing the efficacy of DS-8201a (Trastuzumab deruxtecan) monotherapy in patients with metastatic breast cancer.

Principal investigators

• Pr. Fabrice ANDRÉ ([email protected])
• Dr. Fernanda MOSELE ([email protected])
• Dr. Lusque AMELIE ([email protected])
• Dr. Thomas FILLERON ([email protected])

Data coordinators

• Dr. Marta JIMENEZ ([email protected])
• Dr. Céline MAHIER ([email protected])

Repository organisation

data

This folder contains instructions and documents to be signed to get access to the data. Please see data/README.md for more details.

code

Contains all the code supporting the analyses presented in the paper. See code/README.md for more details.

Contributors

• Bastien JOB https://github.com/aoumess [email protected]
• Loic LE BESCOND https://github.com/loic-lb [email protected]
• Yoann PRADAT https://github.com/ypradat [email protected]